Surrozen, Inc. (SRZN)
$23.51-5.05%Close
BUYCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $176M
- Beta
- 0.56
- P/E (TTM)
- -0.57
- Short % float
- 66.89%
- Days to cover
- 1.5
- SI change
- -0.3%
- 1W
- -10.85%
- 1M
- +31.78%
- vs SPY 1W
- -10.71%
- vs SPY 1M
- +29.28%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 11
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC112.6%
REV YoY-
ROE187.6%
EPS YoY-
ROA-287.3%
GROSS99
OP-385
NET-2885
[VALUATION]
P/E TTM-0.57
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-1.25
P/FCF-
EV/EBITDA-0.24
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO12.14
ND/EBITDA-
BETA0.56
Company news
FAQ
- What is LOPJLB’s current signal on SRZN?
- LOPJLB’s latest quantitative signal on Surrozen, Inc. (SRZN) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is SRZN in?
- Surrozen, Inc. (SRZN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Surrozen, Inc. (SRZN) do?
- Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which …